−6.19USD
−64.47 MUSD
11.78 M
About Jasper Therapeutics, Inc.
Sector
Industry
CEO
Ronald A. Martell
Website
Headquarters
Redwood City
Employees (FY)
45
Founded
2018
ISIN
US4718712023
FIGI
BBG00QPZNP97
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of JSPR is 21.59 USD — it has decreased by 6.98% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Jasper Therapeutics, Inc. stocks are traded under the ticker JSPR.
Jasper Therapeutics, Inc. is going to release the next earnings report on May 10, 2024. Keep track of upcoming events with our Earnings Calendar.
JSPR stock is 10.03% volatile and has beta coefficient of 1.87. Check out the list of the most volatile stocks — is Jasper Therapeutics, Inc. there?
One year price forecast for Jasper Therapeutics, Inc. has a max estimate of 80.00 USD and a min estimate of 55.00 USD.
JSPR earnings for the last quarter are −1.60 USD per share, whereas the estimation was −1.55 USD resulting in a −3.09% surprise. The estimated earnings for the next quarter are −1.61 USD per share. See more details about Jasper Therapeutics, Inc. earnings.
Yes, you can track Jasper Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
JSPR stock has fallen by 25.83% compared to the previous week, the month change is a 16.99% fall, over the last year Jasper Therapeutics, Inc. has showed a 56.45% increase.
JSPR net income for the last quarter is −16.58 M USD, while the quarter before that showed −17.54 M USD of net income which accounts for 5.49% change. Track more Jasper Therapeutics, Inc. financial stats to get the full picture.
Today Jasper Therapeutics, Inc. has the market capitalization of 349.63 M, it has increased by 14.50% over the last week.
No, JSPR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, JSPR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Jasper Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 45.00 employees. See our rating of the largest employees — is Jasper Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Jasper Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Jasper Therapeutics, Inc. stock shows the neutral signal. See more of Jasper Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Jasper Therapeutics, Inc. future price: according to them, JSPR price has a max estimate of 80.00 USD and a min estimate of 55.00 USD. Read a more detailed Jasper Therapeutics, Inc. forecast: see what analysts think of Jasper Therapeutics, Inc. and suggest that you do with its stocks.